After months of debate, state lawmakers have finalized New York’s state budget, opting to preserve access to biomarker testing for Medicaid enrollees. The adopted budget changed language in the historic biomarker testing law, initially passed in 2023, to clarify biomarker testing is covered when it is medically necessary. The law will retain the most important criteria used for determining when testing is to be covered, drawing praise from cancer survivors and patient advocates.